The role of radiotherapy in locally advanced pancreatic carcinoma (Q37772393)

22 August 2017

1 reference

title

The role of radiotherapy in locally advanced pancreatic carcinoma (English)

1 reference

adaptive radiation therapy

22 August 2017

main subject

0 references

3

Ralph R Weichselbaum

1 reference

22 August 2017

Ruchika Gutt

1

1 reference

22 August 2017

Stanley L Liauw

series ordinal

2

1 reference

22 August 2017

language of work or name

English

0 references

publication date

13 July 2010

1 reference

Nature Reviews Gastroenterology & Hepatology

22 August 2017

published in

1 reference

22 August 2017

volume

7

1 reference

22 August 2017

issue

8

1 reference

22 August 2017

page(s)

437-447

1 reference

Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Effects of prolongation of overall treatment time due to unplanned interruptions during radiotherapy of different tumor sites and practical methods for compensation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Combined radiotherapy and chemotherapy (cisplatin and 5-fluorouracil) as palliative treatment for localized unresectable or adjuvant treatment for resected pancreatic adenocarcinoma: results of a feasibility study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

External beam radiotherapy plus 24-hour continuous infusion of gemcitabine in unresectable pancreatic carcinoma: long-term results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Adjuvant therapy in pancreatic cancer: Phase I trial of radiation dose escalation with concurrent full-dose gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Chemoradiotherapy for locally advanced pancreatic cancer: a radiotherapy dose escalation and organ motion study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Induction chemotherapy followed by chemoradiation in locally advanced pancreatic cancer: an effective and well-tolerated treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Past and present treatment of pancreatic adenocarcinoma: chemotherapy as a standard treatment modality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Preoperative chemoradiation in adenocarcinoma of the pancreas. A single centre experience advocating a new treatment strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

21 January 2018

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Randomized controlled trial of the effects of aerobic exercise on physical functioning and quality of life in lymphoma patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Borderline resectable pancreatic cancer: the importance of this emerging stage of disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Impact of Chemoradiotherapy After Disease Control With Chemotherapy in Locally Advanced Pancreatic Adenocarcinoma in GERCOR Phase II and III Studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

The role of diagnostic laparoscopy in pancreatic and periampullary malignancies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

The current role of staging laparoscopy for adenocarcinoma of the pancreas: a review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Hematogenous metastases of pancreatic ductal carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Unresectable adenocarcinoma of the pancreas: patterns of failure and treatment results

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an Eastern Cooperative Oncology Group study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Treatment of pancreatic cancer tumors with intensity-modulated radiation therapy (IMRT) using the volume at risk approach (VARA): employing dose-volume histogram (DVH) and normal tissue complication probability (NTCP) to evaluate small bowel toxicit

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil, leucovorin and cisplatin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Feasibility of preoperative combined radiation therapy and chemotherapy with 5-fluorouracil and cisplatin in potentially resectable pancreatic adenocarcinoma: The French SFRO-FFCD 97-04 Phase II trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Locally advanced pancreatic cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Selective targeting of homologous DNA recombination repair by gemcitabine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Cytotoxic therapy for advanced pancreatic adenocarcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Treatment of advanced pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

New directions in the management of advanced pancreatic cancer: a review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Safety and efficacy of single-day GemOx regimen in patients with pancreatobiliary cancer: a single institution experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

A phase I radiation dose-escalation study to determine the maximal dose of radiotherapy in combination with weekly gemcitabine in patients with locally advanced pancreatic adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Phase I study of concomitant gemcitabine and IMRT for patients with unresectable adenocarcinoma of the pancreatic head

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Translational strategies exploiting TNF-alpha that sensitize tumors to radiation therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

TNFerade Biologic: preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Dose escalation with proton or photon radiation treatment for pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Novel agents for the treatment of adenocarcinoma of the pancreas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

New perspectives in the management of pancreas cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Iodine-125 implant and external beam irradiation in patients with localized pancreatic carcinoma. A comparative study to surgical resection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Long-term results of intraoperative electron beam irradiation (IOERT) for patients with unresectable pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Stereotactic radiotherapy for pancreatic cancer?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Effect on local control and survival of electron beam intraoperative irradiation for resectable pancreatic adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Combined intraoperative radiation and perioperative chemotherapy for unresectable cancers of the pancreas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Using a bigger hammer: the role of stereotactic body radiotherapy in the management of oligometastases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

The use of active breathing control (ABC) to reduce margin for breathing motion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Concomitant administration of weekly oxaliplatin, fluorouracil continuous infusion, and radiotherapy after 2 months of gemcitabine and oxaliplatin induction in patients with locally advanced pancreatic cancer: a Groupe Coordinateur Multidisciplinair

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Pancreatic Resections after Chemoradiotherapy for Locally Advanced Ductal Adenocarcinoma: Analysis of Perioperative Outcome and Survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

A systematic review of resectability and survival after concurrent chemoradiation in primarily unresectable pancreatic cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Phase I/II trial of induction chemotherapy followed by concurrent chemoradiotherapy and surgery for locoregionally advanced pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Survival after pancreatectomy with major arterial resection and reconstruction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: analysis of histopathology and outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Histopathological response to preoperative chemoradiation for resectable pancreatic adenocarcinoma: the French Phase II FFCD 9704-SFRO Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Long-term survival (5-20 years) after pancreatectomy for pancreatic ductal adenocarcinoma: a series of 30 patients collected from 3 institutions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

The HIV protease inhibitor nelfinavir downregulates Akt phosphorylation by inhibiting proteasomal activity and inducing the unfolded protein response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Epidermal growth factor receptor expression in pancreatic carcinoma using tissue microarray technique

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Pancreatic stellate cells potentiate proinvasive effects of SERPINE2 expression in pancreatic cancer xenograft tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Tumor-stroma interaction of human pancreatic cancer: acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Cancer-associated stromal fibroblasts promote pancreatic tumor progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Palliation in pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

The role of radiation therapy in the control of pain from pancreatic carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Radiation therapy in the treatment of irresectable adenocarcinoma of the pancreas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Surgery or endoscopy for palliation of biliary obstruction due to metastatic pancreatic cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Systematic review and meta-analysis of prophylactic gastroenterostomy for unresectable advanced pancreatic cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Treatment of malignant gastric outlet obstruction with endoscopically placed self-expandable metal stents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

An open randomized comparison of clinical effectiveness of protocol-driven opioid analgesia, celiac plexus block or thoracoscopic splanchnicectomy for pain management in patients with pancreatic and other abdominal malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.98

Prognostic factors associated with resectable adenocarcinoma of the head of the pancreas

31 March 2020

1 reference

12 December 2020

[Meta-analysis on gemcitabine of fixed-dose rate infusion plus oxaliplatin as first-line therapy for advanced pancreatic cancer]

1 reference

12 December 2020

Pain relief with short-term irradiation in locally advanced carcinoma of the pancreas.

1 reference

12 December 2020

Multi-drug chemotherapy with and without radiation for carcinoma of the stomach and pancreas: a prospective randomized trial

1 reference

12 December 2020

Intensity-modulated radiation therapy significantly improves acute gastrointestinal toxicity in pancreatic and ampullary cancers

1 reference

12 December 2020

Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group

1 reference

12 December 2020

Combining gemcitabine with radiation in pancreatic cancer: understanding important variables influencing the therapeutic index

1 reference

12 December 2020

Outcomes and tolerability of chemoradiation therapy for pancreatic cancer patients aged 75 years or older

1 reference

12 December 2020

Intraoperatic electron beam irradiation in pancreatic cancer

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRGASTRO.2010.98

1 reference

release_vu2tv52dyjf35ia3qbemwmqxdi

22 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/vu2tv52dyjf35ia3qbemwmqxdi

24 November 2022

mapped directly with Wikidata item

1 reference